Cholangiocarcinoma (CC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Cholangiocarcinoma (CC) is an uncommon form of cancer that affects epithelial cells in the intrahepatic, perihilar, and extrahepatic bile ducts as well as other parts of the biliary system. They are mostly adenocarcinomas (95% of the time) histopathologically. About 10-15% of all hepatobiliary malignancies are cholangiocarcinoma's, which are the second most prevalent primary liver tumours and make up about 3% of gastrointestinal cancers. Key market trends include the rising incidence of cholangiocarcinoma, which is anticipated to fuel the expansion of the worldwide cholangiocarcinoma market throughout the forecast period.

Description

Cholangiocarcinoma (CC) is a rare type of cancer that impacts epithelial cells in the intrahepatic, perihilar, and extrahepatic bile ducts in addition to other areas of the biliary system. Histopathologically, they are primarily adenocarcinomas (in 95% of cases). Since they are typically locally advanced when they are first diagnosed, cholangiocarcinoma's are extremely lethal. Within the liver, 10% of cases are intrahepatic, 40% are distal, and 50% are perihilar. Although surgery is the only curative option, cholangiocarcinoma can be treated medically and surgically. Corrective surgery's efficacy is influenced by the tumor's location, its involvement of the bile ducts, its nodal and metastatic spread, its degree of involvement, and its proximity to important local vasculature. The best surgical outcomes are frequently seen with extrahepatic tumors. Recurrence occurs frequently, even after total resection.

Cholangiocarcinoma (CC) (Epidemiology)

Cholangiocarcinoma is the second-most common primary liver tumours and about 3% of gastrointestinal cancers, account for about 10-15% of all hepatobiliary malignancies. While intrahepatic lesions have become more frequent recently, extrahepatic lesions have become less common. Like many cancers, the likelihood of developing it increases with age, with the 50 to 70 age group having the highest likelihood. Men are diagnosed with cholangiocarcinoma more frequently than women because men have a slightly higher incidence of primary sclerosing cholangitis.

Cholangiocarcinoma (CC) -Current Market Size & Forecast Trends

The cholangiocarcinoma market was valued at approximately USD 952.5 million in 2023 and is projected to reach around USD 2.59 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 11.76% during this period. This growth is driven by several factors, including an aging population, rising incidences of liver diseases, and increased awareness of cholangiocarcinoma, which is leading to more diagnoses. Additionally, advancements in treatment options and diagnostic technologies are enhancing patient outcomes and monitoring capabilities. The North American market is expected to dominate due to its robust healthcare infrastructure, while the Asia Pacific region is anticipated to experience the highest growth rate, fueled by increased research collaborations and healthcare investments. Overall, the market outlook remains positive as new therapies and improved healthcare access continue to evolve through 2035.

The increasing incidence of cholangiocarcinoma is one of the major market trends, and it is expected to drive the growth of the global cholangiocarcinoma market over the course of the forecast period. For instance, statistics from World Cholangiocarcinoma Day in 2016 showed that cholangiocarcinoma was one of the most prevalent malignancies in Thailand, particularly in the north-eastern region. According to the age-standardized incidence rate, Khon Kaen, Thailand, had the highest incidence, with 84 per 100,000 men and 36 per 100,000 women suffering from the condition. Increasing pharmaceutical company R&D initiatives are also anticipated to aid in the growth of the global cholangiocarcinoma market. For instance, two biopharmaceutical firms, Sirnaomics Inc. and Biogen Inc. additionally to Innovent Biologics, Inc. stated their partnership in research and development for the use of the RNAi drug candidate STP705 (Cotsiranib) from Sirnaomics and the antibody drug Tyvyt (Sintilimab injection) from Innovent as a combination therapy for advanced cancers like Hepatocellular Carcinomas (CCA).

Report Highlights

Cholangiocarcinoma (CC) - Current Market Trends

Cholangiocarcinoma (CC) - Current & Forecasted Cases across the G8 Countries

Cholangiocarcinoma (CC) - Market Opportunities and Sales Potential for Agents

Cholangiocarcinoma (CC) - Patient-based Market Forecast to 2035

Cholangiocarcinoma (CC) - Untapped Business Opportunities

Cholangiocarcinoma (CC) - Product Positioning Vis-a-vis Competitors' Products

Cholangiocarcinoma (CC) - KOLs Insight